# CoreWeave, Inc.: overview

CRWV · Nasdaq · CIK 1769628 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crwv.md) · [Financials](/companies/crwv/financials.md) · [Filings](/companies/crwv/filings.md) · [Insiders](/companies/crwv/insiders.md)

Latest reported revenue: [$2.58bn](/filings/0001769628-26-000366.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001769628-26-000366).

## Last eight quarters

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [584](/filings/0001769628-25-000062.md) | [747 d](/filings/0001769628-26-000104.md) | [982](/filings/0001769628-26-000222.md) | [1,212](/filings/0001769628-26-000366.md) | [1,365](/filings/0001769628-25-000062.md) | [1,572 d](/filings/0001769628-26-000104.md) | [2,078](/filings/0001769628-26-000222.md) | [2,575](/filings/0001769628-26-000366.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [20.1%](/filings/0001769628-25-000062.md) | [15.0% d](/filings/0001769628-26-000104.md) | [(2.7%)](/filings/0001769628-26-000222.md) | [1.6%](/filings/0001769628-26-000366.md) | [3.8%](/filings/0001769628-25-000062.md) | [(5.7%) d](/filings/0001769628-26-000104.md) | [(6.9%)](/filings/0001769628-26-000222.md) | [(1.9%)](/filings/0001769628-26-000366.md) |
| Net margin | % | [(61.6%)](/filings/0001769628-25-000062.md) | [(6.8%) d](/filings/0001769628-26-000104.md) | [(32.1%)](/filings/0001769628-26-000366.md) | [(23.9%)](/filings/0001769628-26-000366.md) | [(8.1%)](/filings/0001769628-25-000062.md) | [(28.7%) d](/filings/0001769628-26-000104.md) | [(35.6%)](/filings/0001769628-26-000366.md) | [(24.3%)](/filings/0001769628-26-000366.md) |
| Diluted EPS | $ per share | [(1.82)](/filings/0001769628-25-000062.md) | not reported | [(1.49)](/filings/0001769628-26-000222.md) | [(0.60)](/filings/0001769628-26-000366.md) | [(0.22)](/filings/0001769628-25-000062.md) | not reported | [(1.40)](/filings/0001769628-26-000222.md) | [(1.14)](/filings/0001769628-26-000366.md) |
| Free cash flow | $m | [(574) d](/filings/0001769628-25-000062.md) | [(3,311) d](/filings/0001769628-26-000104.md) | [(1,346)](/filings/0001769628-26-000222.md) | [(2,704) d](/filings/0001769628-26-000366.md) | [(700) d](/filings/0001769628-25-000062.md) | [(2,501) d](/filings/0001769628-26-000104.md) | [(4,711)](/filings/0001769628-26-000222.md) | [(5,743) d](/filings/0001769628-26-000366.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | [229](/filings/0001769628-26-000104.md) | [1,915](/filings/0001769628-26-000104.md) | [5,131](/filings/0001769628-26-000104.md) |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | [(6.1%)](/filings/0001769628-26-000104.md) | [16.9%](/filings/0001769628-26-000104.md) | [(0.9%)](/filings/0001769628-26-000104.md) |
| Net margin | % | [(259.4%)](/filings/0001769628-26-000104.md) | [(45.1%)](/filings/0001769628-26-000104.md) | [(22.7%)](/filings/0001769628-26-000104.md) |
| Diluted EPS | $ per share | [(3.09)](/filings/0001769628-26-000104.md) | [(4.30)](/filings/0001769628-26-000104.md) | [(2.81)](/filings/0001769628-26-000104.md) |
| Free cash flow | $m | [(1,110)](/filings/0001769628-26-000104.md) | [(5,953)](/filings/0001769628-26-000104.md) | [(7,251)](/filings/0001769628-26-000104.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crwv/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Magnetar Financial LLC](/funds/1352851.md) | 2026-06-30 | $5.18bn | 52,062,927 |  | Reduced −16,503,467 |
| [NVIDIA CORP](/funds/1045810.md) | 2026-06-30 | $4.70bn | 47,213,353 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.40bn | 24,105,966 |  | Added +14,727,734 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $2.19bn | 21,991,800 | Put | Reduced −2,538,100 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $1.80bn | 18,103,949 |  | Added +226,302 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.70bn | 17,063,815 |  | Added +4,353,457 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.57bn | 15,789,271 |  | Added +3,351,876 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $1.55bn | 15,601,500 | Call | Added +1,906,300 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $1.38bn | 13,885,024 |  | Added +5,028,333 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.33bn | 13,389,400 | Call | Reduced −6,612,800 |

## Recent filings

[All 1,152 filings](/companies/crwv/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-22 | 16:17 ET | [8-K](/filings/0001769628-26-000432.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001769628-26-000432 |
| 2026-09-17 | 07:13 ET | [8-K](/filings/0001769628-26-000429.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001769628-26-000429 |
| 2026-08-12 | 19:24 ET | [10-Q](/filings/0001769628-26-000366.md) | Quarterly report, period 2026-06-30 | 0001769628-26-000366 |
| 2026-08-11 | 16:10 ET | [8-K](/filings/0001769628-26-000362.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001769628-26-000362 |
| 2026-08-10 | 16:10 ET | [8-K](/filings/0001769628-26-000357.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001769628-26-000357 |
| 2026-06-18 | 16:09 ET | [8-K](/filings/0001769628-26-000291.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001769628-26-000291 |
| 2026-06-11 | 06:03 ET | [8-K](/filings/0001769628-26-000278.md) | 7.01 Regulation FD disclosure | 0001769628-26-000278 |
| 2026-06-10 | 16:20 ET | [8-K](/filings/0001769628-26-000270.md) | 5.07 Shareholder vote results | 0001769628-26-000270 |
| 2026-05-18 | 16:06 ET | [8-K](/filings/0001769628-26-000236.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001769628-26-000236 |
| 2026-05-08 | 19:21 ET | [10-Q](/filings/0001769628-26-000222.md) | Quarterly report, period 2026-03-31 | 0001769628-26-000222 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001769628-26-000104.md), filed Mar 2, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c0d81019-ae14-4f53-a6e3-ca1717feef9c)

## About the filer

- CIK: 1769628
- Tickers: CRWV
- Exchange: Nasdaq
- SIC code: 7372 Services-Prepackaged Software
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:41 ET. No prices; not investment advice.